Jiangsu Hengrui Pharmaceuticals (01276): SHR-1139 injection approved for clinical trials

Jiangsu Hengrui Pharmaceuticals (01276) announced that its subsidiary, Guangdong Jiangsu Hengrui Pharmaceuticals Co., Ltd., has recently received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for SHR-1139 injection, and will soon commence clinical trials. SHR-1139 injection is a biopharmaceutical developed independently by the company, which is expected to synergistically enhance the treatment of ulcerative colitis by inhibiting inflammatory reactions and maintaining epithelial barriers. Currently, there are no similar drugs approved for marketing domestically or internationally. As of now, the accumulated research and development investment for SHR-1139 injection is approximately RMB 71.28 million.